Targeting Cancer Using Fragment Based Drug Discovery

Author(s): Andrew P. Turnbull, Susan M. Boyd.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 12 , Issue 1 , 2012

Submit Manuscript
Submit Proposal

Abstract:

Over the past decade, fragment-based drug discovery has developed significantly and has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening approaches for hit identification. Fragment-based methods are capable of rapidly identifying starting points for structure-based drug design from relatively small libraries of low molecular weight compounds. The main constraints are the need for sensitive methods that can reliably detect the typically weak interactions between fragments and the target protein, and strategies for transforming fragments into higher molecular weight drug candidates. This approach has recently been validated as series of compounds from various programs have entered clinical trials.

Keywords: Fragment screening, Ligand efficiency, Drug discovery, Cancer, high-throughput screening (HTS), Crystallography, fluorimetry, Phosphoinositide-Dependent Kinase-1 (PDK1), Anti-cancer, Cyclindependent kinase (CDK)

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 1
Year: 2012
Page: [40 - 48]
Pages: 9
DOI: 10.2174/187152012798764660

Article Metrics

PDF: 24